{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:23:24Z","timestamp":1791487404225,"version":"4.3.4"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n People with HIV (PWH) experiencing homelessness face barriers to daily oral antiretroviral therapy (ART) adherence and often lack access to HIV specialty care. Data are needed on the feasibility and outcomes of long-acting ART (LA-ART) delivery within low-barrier, community-based settings.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the implementation and effectiveness of LA-ART delivery at a community-based drop-in clinic for people experiencing homelessness (PEH).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This quality improvement study included PWH experiencing homelessness or housing instability, among whom substance use and psychiatric disorders were prevalent, receiving care at the Maria X. Martinez Health Resource Center, a municipal clinic serving PEH in San Francisco, California. Programmatic outcomes of LA-ART were evaluated from November 2021 through October 2025, with a secondary descriptive evaluation of PWH receiving standard treatment vs LA-ART between January 2023 and December 2024.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Intramuscular cabotegravir-rilpivirine injection, with or without lenacapavir, delivered within a high-touch model incorporating reminders, outreach, and flexible delivery compared with standard treatment consisting of oral ART when accepted.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes were viral suppression (HIV RNA &amp;lt;200 copies\/mL) and clinical encounters per person-year between 2023 and 2024. Among LA-ART recipients, additional outcomes included retention, injection timeliness, out-of-clinic administration, and virologic failure over the full program period.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 128 PWH included in the 2023-2024 descriptive cohort, 24 individuals (mean [SD] age, 44.6 [12.2] years; 15 cisgender males [63%]) received LA-ART, and 123 individuals (mean [SD] age, 42.6 [12.1] years; 69 cisgender males [66%]) received standard treatment (due to treatment transitions, treatment conditions were not mutually exclusive). All 24 (100%) individuals receiving LA-ART achieved and maintained viral suppression. Among those receiving standard treatment, 89 of 123 (72%) ever achieved viral suppression and 69 of 123 (56%) had viral suppression at last follow-up. The mean (SD) number of clinical encounters per person-year was higher for LA-ART recipients (23.0 [11.1] vs 9.1 [11.5]). Across the full program period, 30 individuals initiated LA-ART, and all continued receiving therapy through October 2025 (median duration [range], 106 [8-206] weeks). Of 637 injection visits, 43 (7%) were delayed by more than 7 days and 21 (3%) by more than 14 days, and 121 (19%) were administered outside the clinic. Three individuals experienced virologic failure while receiving cabotegravir-rilpivirine and achieved resuppression after the addition of lenacapavir.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this quality improvement study, LA-ART delivery within a high-touch, flexible care model in a drop-in clinic serving PEH was associated with high rates of viral suppression. These findings highlight the potential for nonspecialty, community-based settings to deliver LA-ART to structurally vulnerable populations, while underscoring the substantial programmatic support required.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.20348","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:31:37Z","timestamp":1782487897000},"page":"e2620348","source":"Crossref","is-referenced-by-count":1,"title":["Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care"],"prefix":"10.1001","volume":"9","author":[{"given":"Nicky J.","family":"Mehtani","sequence":"first","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"},{"name":"Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Matzat","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen B.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Strieff","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Strough","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan M.","family":"Philbin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory O.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Zevin","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California"},{"name":"Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"2","key":"zoi260570r1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/cid\/cix295","article-title":"Prevalence of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus among homeless and nonhomeless United States veterans.","volume":"65","author":"Noska","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi260570r2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10900-022-01119-y","article-title":"Access to healthcare and the utilization of sexually transmitted infections among homeless Medicaid patients 15 to 44 years of age.","volume":"47","author":"Patel","year":"2022","journal-title":"J Community Health"},{"issue":"11","key":"zoi260570r3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1473-3099(12)70177-9","article-title":"Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis.","volume":"12","author":"Beijer","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"zoi260570r4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2015.302905","article-title":"Housing status, medical care, and health outcomes among people living with HIV\/AIDS: a systematic review.","volume":"106","author":"Aidala","year":"2016","journal-title":"Am J Public Health"},{"issue":"9","key":"zoi260570r5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/QAD.0000000000003570","article-title":"Experiencing homelessness and progression through the HIV cascade of care among people who use drugs.","volume":"37","author":"Reddon","year":"2023","journal-title":"AIDS"},{"key":"zoi260570r6","doi-asserted-by":"publisher","first-page":"S353","DOI":"10.1093\/infdis\/jiac267","article-title":"HIV treatment outcomes in POP-UP: drop-in HIV primary care model for people experiencing homelessness.","volume":"226","author":"Hickey","year":"2022","journal-title":"J Infect Dis"},{"issue":"12","key":"zoi260570r7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260570r8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"issue":"10267","key":"zoi260570r9","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"zoi260570r10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV.","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"16","key":"zoi260570r11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jama.2025.0109","article-title":"HIV Viral suppression with use of long-acting antiretroviral therapy in people with and without initial viremia.","volume":"333","author":"Spinelli","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"zoi260570r12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir\/rilpivirine with initial viremia.","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi260570r13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000003396","article-title":"Feasibility of implementing a low-barrier long-acting injectable antiretroviral program for HIV treatment and prevention for people experiencing homelessness.","volume":"96","author":"Mehtani","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"zoi260570r15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA panel.","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"issue":"19","key":"zoi260570r16","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi260570r17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America.","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"8","key":"zoi260570r18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1089\/apc.2023.0061","article-title":"The CARES program: improving viral suppression and retention in care through a comprehensive team-based approach to care for people with HIV and complex psychosocial needs.","volume":"37","author":"Sweitzer","year":"2023","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"zoi260570r19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1089\/apc.2017.0313","article-title":"The Max Clinic: medical care designed to engage the hardest-to-reach persons living with HIV in Seattle and King County, Washington.","volume":"32","author":"Dombrowski","year":"2018","journal-title":"AIDS Patient Care STDS"},{"issue":"12","key":"zoi260570r20","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1007\/s10461-023-04110-3","article-title":"Substance use and mental health comorbidities and receipt of specialty care among patients enrolled in a low-barrier HIV clinic.","volume":"27","author":"Altwies","year":"2023","journal-title":"AIDS Behav"},{"issue":"6","key":"zoi260570r21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf330","article-title":"HIV viral suppression with unintentional lenacapavir monotherapy in adherence-challenged patients: a case series.","volume":"12","author":"Mehtani","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"13","key":"zoi260570r22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.2025.13518","article-title":"The One Big Beautiful Bill Act\u2014implications for rural health care.","volume":"334","author":"Howren","year":"2025","journal-title":"JAMA"},{"key":"zoi260570r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.4849","article-title":"New Medicaid enrollment barriers and lessons from unwinding.","author":"McIntyre","year":"2025","journal-title":"JAMA Health Forum"},{"key":"zoi260570r14","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalinfoHIV.gov. Updated September 25, 2025. Accessed September 25, 2025. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850840\/mehtani_2026_oi_260570_1781805561.94599.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:31:44Z","timestamp":1782487904000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.20348","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}